Exenatide vs Tirzepatide
Last updated
Compare the ingredients, then check the specific brand, formulation, and dose. Approved uses and prices vary by product.
Exenatide vs Tirzepatide: lowest prices now


Tirzepatide: lowest compounded on a monthly plan, not FDA-approved
$69/mo + $199/yr membership · about $86 a month over a year with the membership · first order: membership free for the first 21 days, never charged if you cancel before
| Compare | Exenatide | Tirzepatide |
|---|---|---|
| What it is for | FDA-approved for
| FDA-approved for
|
| Brands | Mounjaro, Zepbound GIP/GLP-1 | |
| Route & frequency | Subcutaneous injection Twice daily (Byetta); once weekly (Bydureon BCise) | Subcutaneous injection Once weekly |
| FDA shortage report | National reporting does not confirm stock at your pharmacy. Coverage & source records | National reporting does not confirm stock at your pharmacy. Coverage & source records |
Direct comparative evidence
No direct comparative trial is included for these ingredients in our reviewed catalog. The separate trial results below do not establish which works better.
What the quoted price covers
Lowest tracked quotes for FDA-approved products, selected separately for each price basis. Entry prices may refer to different brands or formulations. Supply periods, eligibility, refill deadlines, and additional fees can change what you pay.
| Compare | Exenatide | Tirzepatide |
|---|---|---|
| Advertised entry price | ~$422 per pen (goodrx.com/exenatide) Generic exenatide (Amneal) GoodRx GoodRx coupon, lowest listed price for one 5 mcg pen (60 doses: 30 days at the twice-daily dose) Third-party reported priceDays of supply not on record; not ranked per 30 days. Checked on goodrx.com Price conditionsGoodRx coupon, lowest listed price for one 5 mcg pen (60 doses: 30 days at the twice-daily dose) Every exenatide product is now discontinued: the FDA withdrew the Byetta and Bydureon approvals in 2025, and Amneal's generic is listed by the FDA as discontinued too. Pharmacies may still dispense remaining stock. | $299/28 days (pharmacy.amazon.com/ZEPBOUND-KWIKPEN-2-5-MG-DOSE-PEN-INJ/dp/B0GP27N9T3) Zepbound KwikPen via Amazon Pharmacy Amazon Pharmacy without insurance, 2.5 mg; includes the manufacturer coupon if eligible (list price $498.98); prescription required 28-day supply (pharmacy.amazon.com) ≈ $320.36 per 30 days at this quoted rate Offer through Checked on pharmacy.amazon.com Price conditionswithout insurance, 2.5 mg; includes the manufacturer coupon if eligible (list price $498.98); prescription required The 7.5 mg KwikPen is also $449. Amazon fills a prescription you already have and delivers in all 50 states. FDA-approved product. 28-day supply |
| At the named trial dose | No sourced quote tracked for this price basis. | $449/28 days (pharmacy.amazon.com/ZEPBOUND-KWIKPEN-15-MG-DOSE-PEN-INJ/dp/B0GP1V2X9V) Zepbound KwikPen via Amazon Pharmacy At 15 mg Amazon Pharmacy without insurance, with Lilly's self-pay card, which ends 12/31/2026 and requires each refill within 45 days of the previous delivery, as Lilly's Zepbound savings page states (otherwise Lilly's regular $699); 15 mg; includes the manufacturer coupon if eligible (list price $699) 28-day supply (pharmacy.amazon.com) ≈ $481.07 per 30 days at this quoted rate Offer through Checked on pharmacy.amazon.com Price conditionswithout insurance, with Lilly's self-pay card, which ends 12/31/2026 and requires each refill within 45 days of the previous delivery, as Lilly's Zepbound savings page states (otherwise Lilly's regular $699); 15 mg; includes the manufacturer coupon if eligible (list price $699) The 7.5 mg KwikPen is also $449. Amazon fills a prescription you already have and delivers in all 50 states. FDA-approved product. 28-day supply |
| Every offer | See the offer | All 885 offersAll 885 tirzepatide offers |
USD self-pay, not insurance or pharmacy acquisition cost. A trial dose is not a personal dosing recommendation. Compounded offers are shown separately in the offer browser and are not FDA-approved.
Trial outcomes in context
Each result belongs to its own trial, population, dose, and analysis. Weight loss, HbA1c change, and adverse events may come from different studies even within one ingredient. These are study averages, not predictions of your result.
| Compare | Exenatide | Tirzepatide |
|---|---|---|
| Weight change | ≈−4% (diabetesjournals.org/care/article/33/6/1255/27340/DURATION-1-Exenatide-Once-Weekly-Produces) (-4.1 kg (~4% of the 102 kg baseline) at 52 wks · DURATION-1 · 2 mg weekly (Bydureon)) -4.1 kg (~4% of the 102 kg baseline) at 52 wks DURATION-1 (diabetesjournals.org)2 mg weekly (Bydureon) Approximation from kilograms; see trial methods Study contextThe oldest GLP-1; a diabetes trial with a modest weight effect. | −20.9% (nejm.org/doi/full/10.1056/NEJMoa2206038) (-20.9% at 72 wks · SURMOUNT-1 · 15 mg weekly (Zepbound)) -20.9% at 72 wks SURMOUNT-1 (nejm.org)15 mg weekly (Zepbound) Accounts for treatment discontinuation Study contextSURMOUNT-1 studied adults with obesity or overweight without diabetes. This result belongs to the 15 mg arm and the treatment-regimen analysis; other doses and analyses have different results. |
| HbA1c change (percentage points) | −1.9 pp (pubmed.ncbi.nlm.nih.gov/18782641) (-1.9% at 30 wks · DURATION-1 · HbA1c change in percentage points) -1.9 percentage points at 30 wks DURATION-1 (pubmed.ncbi.nlm.nih.gov) | −2.3 pp (investor.lilly.com/news-releases/news-release-details/lillys-surpass-2-results-published-new-england-journal-medicine) (-2.3% at 40 wks · SURPASS-2 · HbA1c change in percentage points) -2.3 percentage points at 40 wks SURPASS-2 (investor.lilly.com) |
| Adverse events | Stopped treatment for adverse events 3.9% (accessdata.fda.gov/drugsatfda_docs/label/2024/209210s024lbl.pdf) (3.9% discontinued for adverse reactions · Bydureon BCise FDA label (2 mg, type 2 diabetes))Reported nausea 8.2% (accessdata.fda.gov/drugsatfda_docs/label/2024/209210s024lbl.pdf) (Nausea in the drug arm · Bydureon BCise FDA label (2 mg, type 2 diabetes))Bydureon BCise FDA label (2 mg, type 2 diabetes) from the FDA label adverse-reactions table (DURATION-1 does not cleanly report AE discontinuation); a diabetes population | Stopped treatment for adverse events 6.2% (nejm.org/doi/full/10.1056/NEJMoa2206038) (6.2% vs 2.6% placebo (15 mg) · SURMOUNT-1 (15 mg, 72 wks, obesity))Reported nausea 31% (nejm.org/doi/full/10.1056/NEJMoa2206038) (Nausea in the drug arm · SURMOUNT-1 (15 mg, 72 wks, obesity))SURMOUNT-1 (15 mg, 72 wks, obesity) |
Timing, generics and coverage
Read from each FDA label, FDA's Orange Book and CMS's Part D files, and updated when they change.
| Brand | Soonest top dose | Half-life | Generic approved? | Patent on the medicine to | On Medicare Part D, 2025 |
|---|---|---|---|---|---|
| Mounjaro | 15 mg from week 21 | about 5 days | No | Jun 14, 2039 | 1,592,517 |
| Zepbound | 15 mg from week 21 | about 5-6 days | No | May 13, 2036 | 160,298 |
How long each takes · Generics and patents · Who covers what
Approved uses & full records
Exenatide
Indications depend on the brand and formulation. Read the product-specific indications and prescribing information in the full record.
381 registered ingredient studies (clinicaltrials.gov/search). Count checked . Research activity, not a measure of evidence quality.
Open full recordTirzepatide
Indications depend on the brand and formulation. Read the product-specific indications and prescribing information in the full record.
317 registered ingredient studies (clinicaltrials.gov/search). Count checked . Research activity, not a measure of evidence quality.
Open full recordCommon questions
Is Exenatide or Tirzepatide better for weight loss?
No trial on our list compared them directly. In separate trials: Exenatide -4.1 kg (~4% of the 102 kg baseline) at 52 wks in DURATION-1 (2 mg weekly (Bydureon)) (diabetesjournals.org); Tirzepatide -20.9% at 72 wks in SURMOUNT-1 (15 mg weekly (Zepbound)) (nejm.org). Separate trials enrolled different people for different lengths of time, so these figures cannot rank them.
Is Exenatide or Tirzepatide safer?
We know of no trial set up to answer that. Stopping because of side effects, each in its own trial and not a head-to-head figure: Exenatide 3.9% discontinued for adverse reactions (Bydureon BCise FDA label (2 mg, type 2 diabetes)) (accessdata.fda.gov); Tirzepatide 6.2% vs 2.6% placebo (15 mg) (SURMOUNT-1 (15 mg, 72 wks, obesity)) (nejm.org). Each FDA label lists its own warnings, and which ones matter depends on your health.
What Tirzepatide dose is equivalent to Exenatide?
No FDA label sets a dose of Exenatide that equals a dose of Tirzepatide, and we know of no trial that defines one. Switching is a prescriber's decision, and each label sets its own starting dose and steps.
Which costs less: Exenatide or Tirzepatide?
Compare the named products and price conditions below. A tracked entry quote can be a different brand or formulation from the product studied in a trial. A trial-dose quote applies only to the named product and dose; neither figure is an estimate of your whole treatment cost or an insurance quote.
Do these trial results tell me which medication is best?
Direct trials compare the treatments, doses, and participants they studied. Results from separate trials differ in population, duration, dose, and analysis, so their percentages do not establish a treatment ranking. Discuss your medical history and the specific product label with a licensed clinician.
Does FDA shortage status mean my pharmacy has stock?
No. FDA shortage records describe national supply reports and covered presentations, not inventory at an individual pharmacy. Unknown status means the data cannot establish a current assessment. Confirm local stock with your pharmacy.
What changed for Exenatide and Tirzepatide
- PriceProtocol MD: Compounded tirzepatide via Protocol MD now $299/mo (was $319/mo) (read on protocolmd.com)
- PriceCorrected: Telezen MD, Compounded tirzepatide via Telezen MD, $228/mo on its own page (we had from $159/mo) (read on telezenmd.com)
- PriceCorrected: Ascend Vitality, Compounded tirzepatide via Ascend Vitality, $199/mo on its own page (we had from $119/mo) (read on av-life.com)
- PriceNexLife: Microdose tirzepatide via NexLife now $129/mo (was $159/mo) (read on nexlife.com)
- PriceRow Telehealth: Compounded tirzepatide via Row Telehealth now $249/mo (was from $249/mo) (read on rowtelehealth.com)
- PriceRow Telehealth: Compounded tirzepatide dissolving tablets (ODT) via Row Telehealth now $229/mo (was from $229/mo) (read on rowtelehealth.com)
Written from each source's own record as it changes. Every change on GLPcompare
Automated feed checks do not constitute a clinical or editorial review. Sources & methodology